0001209191-19-060041.txt : 20191211
0001209191-19-060041.hdr.sgml : 20191211
20191211163011
ACCESSION NUMBER: 0001209191-19-060041
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191209
FILED AS OF DATE: 20191211
DATE AS OF CHANGE: 20191211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morl Christopher John
CENTRAL INDEX KEY: 0001716821
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 191280079
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC
STREET 2: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-09
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001716821
Morl Christopher John
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM
MA
02451
0
1
0
0
Chief Business Officer
Common Stock
2019-12-09
4
M
0
3387
3.95
A
3387
D
Common Stock
2019-12-09
4
S
0
3387
55.00
D
0
D
Common Stock
2019-12-10
4
M
0
11647
3.95
A
11647
D
Common Stock
2019-12-10
4
S
0
11647
55.00
D
0
D
Stock Option (Right to Buy)
3.95
2019-12-09
4
A
0
3387
0.00
A
2026-10-20
Common Stock
3387
222127
D
Stock Option (Right to Buy)
3.95
2019-12-10
4
A
0
11647
0.00
A
2026-10-20
Common Stock
11647
210480
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of October 3, 2016, subject to continued service through such dates.
/s/ Jeffrey M. Held, Attorney-in-Fact
2019-12-11